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Objective: Adequate treatment of a first psychotic episode in young people is a difficult challenge but may be of critical im-
portance for changing the course of psychotic illness. Pharmacotherapy is the standard treatment of psychosis, however there 
is a paucity of data specific to first-episode psychosis.
Methods: In this study 12 young people who presented with a psychotic episode at a specialised early intervention service 
were commenced on treatment with aripiprazole. They were assessed at baseline and weeks 4, 6, 24 and 48 using a broad 
battery of outcome measures. Case notes were also examined.
Results: Data was available for 6 participants at week 48, and of those, one remained on treatment with Aripiprazole at endpoint. 
Case histories were typified by presentations that included illicit substance use and treatments characterised by several changes 
in medications. No single treatment choice predominated. Most participants tolerated treatment and showed symptomatic im-
provement with individualised therapy.
Conclusion: Most participants showed improvement during the treatment period. Aripiprazole was one of many medications used 
in this study and may have been useful for the treatment of some individuals with first episode psychosis.
KEY WORDS: Aripiprazole; First-episode psychosis; Treatment; Outcomes; Schizophrenia; Bipolar disorder.
INTRODUCTION
The onset of psychotic disorders is most commonly in 
late adolescence or early adulthood.1,2) This is a critical pe-
riod in the psychological, social and educational develop-
ment of the young person. Disruptions in this period can 
lead to significant disability in many areas of psychosocial 
functioning including family and peer relationships and 
vocational opportunities. Much attention has been fo-
cused recently on strategies to increase early identi-
fication of psychotic illness, optimise treatment ap-
proaches, reduce overall disability and improve long- 
term outcomes.3,4) This has led to the development of a 
number of early intervention services around the world.
The Australian Clinical Guidelines on the management 
of first episode psychosis recommends that early treat-
ment of first presentation psychosis should include psy-
chological and pharmacological treatments and a range of 
family and group interventions.5) Finding acceptable 
treatments in this phase can often be difficult for the in-
dividual experiencing mental illness for the first time. In 
particular many medications, including the second gen-
eration antipsychotics can have a range of distressing side 
effects including weight gain, lipid changes, endocrine ef-
fects and sedation.6) Unacceptable side effect profiles are 
likely to lead to decreased rates of adherence and may af-
fect overall outcome. Effective treatments are essential as 
compliance is also associated with treatment response.7) 
Treatment outcome in this young population is also com-
plicated by a higher prevalence of substance use,7) non- 
specific symptomatology,8) less insight9) and miscon-
ceptions about mental illness.10)
Aripiprazole is a second generation antipsychotic with 
a uniquely different pharmacological profile compared to 
other antipsychotic drugs. It is a D2 dopamine receptor and 
5-HT1A serotonin receptor partial agonist and a 5-HT2A 
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antagonist. It is reported to be safe and well tolerated at 
doses up to 30 mg.11) Aripiprazole treatment of schizo-
phrenia has been shown to be superior to placebo for im-
provement in PANSS Total, Negative and Positive scores 
and CGI-Severity scores. Aripiprazole is not associated 
with extrapyramidal symptoms, increases in prolactin or 
weight changes.12)
Aripiprazole was demonstrated to be superior to place-
bo at 10 mg/day and 30 mg/day doses for a reduction in 
PANSS Total score in a 6-week randomised, double-blind, 
trial of adolescents aged 13 to 17 years old with a DSM-IV 
diagnosis of schizophrenia.13)
These findings make aripiprazole a potentially useful 
option for use in a first-episode psychosis population. The 
usefulness of aripiprazole for the treatment of first episode 
psychosis in a specialist early intervention service has not 
previously been investigated. In this article we present the 
clinical outcomes for patients at a specialist early inter-
vention service who commenced treatment with aripipra-
zole as a first-line treatment for a psychotic episode.
The original aim of the study was to examine the utility 
of aripiprazole and the optimal initial dosing paradigm in 
15 to 25 year olds for the treatment of a first episode of 
psychosis. The relationship of dosage to outcome was in-
tended to be investigated. The original hypothesis was; 
that treatment with aripiprazole would be associated with 
improvement in symptomatic, functional and vocational 
outcomes in first episode patients and that the magnitude 
of the improvement will be greater with higher dosage. 
However, as fewer than expected participants were re-
cruited the study was not sufficiently powered for analysis 
by dose. Consequently, this manuscript documents the us-
age of aripiprazole in a treatment program for first episode 
psychosis in a series of 12 cases.
METHODS
A naturalistic, prospective, single centre study was con-
ducted, and included all eligible patients meeting criteria 
for first episode psychosis referred to the service. People 
aged 15 to 25 years presenting at a specialised early inter-
vention service in Geelong, Australia in 2007-2008 for a 
first episode of psychosis were, if clinically indicated and 
with no contraindications, treated with aripiprazole as a 
first line antipsychotic. Early psychosis services were set 
up in Australia to provide a clinical approach to those ex-
periencing symptoms of psychosis for the first time, as 
part of a new prevention paradigm for psychiatry.8,14)
A first episode of psychosis was defined as daily psy-
chotic symptoms occurring for more than a week that 
could not be explained by other means (e.g. drug induced 
or organic). All participants met clinical criteria for pre-
scription of an antipsychotic medication. Participants with 
DSM-IV diagnoses of schizophreniform psychosis, schiz-
ophrenia, delusional disorder or psychosis NOS were 
included. Participants needed to be utilising effective con-
traception if female and sexually active. Participants were 
excluded from the study if they had received previous 
treatment with an antipsychotic for more than 1 week, had 
psychotic symptoms due to an organic syndrome (e.g. 
brain tumour, temporal lobe epilepsy), had a substance- 
induced psychosis, had a history of a significant medical 
condition contra-indicating the use of aripiprazole, had a 
previous adverse reaction to aripiprazole, had a known al-
lergy to aripiprazole or its contents, if there was cognitive 
impairment that would impede the participants ability to 
give informed consent, were pregnant or lactating women, 
if there was non fluency in English or if the participant had 
a history of epilepsy.
The treating psychiatrist made all treatment decisions. 
The treating psychiatrist, if he or she felt that aripiprazole 
was no longer indicated because of lack of response or 
poor tolerability, could withdraw aripiprazole and pre-
scribe an alternative drug. Dosing regimes were flexible 
and based on clinical response. There were no restrictions 
to additional medication being prescribed if clinically in-
dicated (including antidepressants, benzodiazepines, mood 
stabilizers or anticholinergics). Patients who commenced 
aripiprazole were evaluated as study participants using 
data collected as routine outcome measures. Where possi-
ble data was still collected even if participants had dis-
continued treatment with aripiprazole.
A suite of outcome measures which are mandatory in 
public mental health services in Victoria, Australia, where 
completed by clinicians or participants over a 48-week 
period. These included the clinician rated measures 
[Health of the Nation Outcomes Scales (HoNOS), the Life 
Skills Profile (LSP)15)] and a consumer-rated measure 
[Behaviour and Symptom Identification Scale (BASIS 
32)15)]. Additional assessments were conducted by trained 
clinicians at baseline and weeks 4, 6, 24 and 48. The as-
sessment schedule is described in Table 1.
Treatment followed accepted Australian treatment 
guidelines for the treatment of schizophrenia and related 
disorders.5) The Barwon Health Research and Ethics 
Advisory Committee gave ethical approval for the study. 
The nonparametric Wilcoxon’s signed-rank test was used 
to compare baseline and each subsequent visit scores. 
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Table 1. Assessment schedule for first-episode psychosis patients treated with aripiprazole
Baseline Week 2 Week 6 Week 24 Week 48
Data collected
throughout study period
Vital signs (pulse, blood pressure) X
Weight and body mass index X
Electrocardiogram X
Blood (FBE, LFT, TFT, U&E, Cholesterol/lipids, Glucose) X
Medications X
Psychosocial treatments X
HoNOS X X X
LSP X X X
Social and occupational functioning
Assessment scale (SOFAS)
X X X X
GAF X X X X
BPRS X X X X
CGI X X X X
Suicide risk indicator X
Substance use indicator X
Early psychosis flag X
BAS X X X X
SARS X X X X
BASIS 32 X X
RESULTS
Twelve patients participated in the study, 3 females 
aged 22.33±3.06 years and 9 males aged 21.25±2.38 years 
(mean±SD). Only 1 participant remained on treatment 
with aripiprazole from baseline to week 48. Eleven partic-
ipants commenced treatment with aripiprazole at baseline 
(mean dose±SD: 7.32±3.89 mg/day) and one was on no 
medication at baseline but treated with aripiprazole (5 
mg/day) at week 4.
Clinical details were available for most participants. All 
participants had been treated following a psychotic 
episode. Alcohol and substance use was a significant fac-
tor for all participants, and had been a precipitant of the 
psychotic episode for at least 4 participants. Alcohol use, 
including dependence and abuse, was reported by 6 
participants. Cannabis use up to 1 g/day was reported by 9 
participants. Polysubstance use, including dependence, 
was reported by 6 participants. Other drugs used by partic-
ipants included tobacco, amphetamine, ecstasy, ketamine, 
ice, heroin and inhaling organic solvents (chroming). 
Three participants were diagnosed with paranoid schizo-
phrenia, one with schizophrenia and one with schizo-
phrenia and depression with paranoid persecutory themes 
following using alcohol and cannabis. Other participants 
were given diagnoses associated with the index episode, 
such as schizophreniform psychosis or psychotic disorder 
NOS. Individuals with a clinical diagnosis of sub-
stance-induced psychotic disorder were excluded. Two 
participants were reported to have cluster B personality 
traits in addition to a psychotic episode. Two participants 
reported periods of homelessness including one who had 
been sleeping on a local beach prior to hospital admission. 
Suicidality or self-harm were not present in any of the 
participants.
At week 4, there were 4 participants who had dis-
continued treatment with aripiprazole. One was switched 
to risperidone and later treated with olanzapine, ziprasi-
done, venlafaxine and quetiapine. Another participant 
was receiving fluoxetine monotherapy by week 4 and was 
case-closed by week 48. A third was switched to olanza-
pine and later switched to risperidone consta and a forth 
was switched to quetiapine and later to olanzapine. No da-
ta on reasons for discontinuation of aripiprazole were re-
corded, however no serious adverse events were reported 
for any of the study participants during the study period. 
At week 6 a further participant discontinued aripiprazole, 
was treated with quetiapine, valproate and venlafazine 
and was case-closed by week 48. At week 24 a further two 
participants discontinued aripiprazole, one switching to 
risperidone consta and the other switching to olanzapine, 
and a third participant was lost to follow-up, with only 4 
participants remained on aripiprazole treatment (mean 
dose±SD: 15±11 mg/day). By week 48 a further three par-
ticipants had discontinued aripiprazole, one switching to 
olanzapine and the other two with medications not 
recorded. Only 1 participant remained on aripiprazole 
treatment at week 48 (dose 15 mg/day). The aripirazole 
dose trended upward until discontinuation in most partic-
ipants, but was stable in the one participant who did not 
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Table 2. Median rating scale scores in each study visit in patients with first episode psychosis
Measure Baseline (n=12) Week 4 (n=12) Week 6/8 (n=12) Week 24 (n=9) Week 48 (n=6)
BPRS
Median (IQR) 51 (43-55) 29 (26-32) 24 (17-28) 21 (16-25)
p-value (baseline to each visit) 0.003 0.011 0.028
p-value (between current and previous visit) 0.286 0.833
CGI-S
Median (IQR) 5 (4-6)  4 (3-4)  3 (2-4)  2 (1-4)
p-value (baseline to each visit) 0.003 0.009 0.043
p-value (between current and previous visit) 0.246 0.914
SOFAS
Median (IQR) 40 (16-49) 51 (46-64) 61 (50-78) 80 (54-83)
p-value (baseline to each visit) 0.003 0.013 0.027
p-value (between current and previous visit) 0.671 0.394
GAF
Median (IQR) 33 (26-49) 50 (40-60) 60 (51-80) 76 (50-86)
p-value (baseline to each visit) 0.003 0.011 0.028
p-value (between current and previous visit) 0.086 1.000
Results shown as median (interquartile range). Differences between visits compared with Wilcoxon’s signed-rank test.
discontinue aripiprazole treatment. Ten subjects switched 
from aripiprazole to another antipsychotics on the basis of 
clinician decision, which included consideration of pa-
tient or clinician preference, tolerability and efficacy. 
Five participants had known histories of treatment ini-
tiation prior to commencing treatment with aripiprazole. 
During aripiprazole treatment many other medications 
were prescribed to some of the participants. These include 
one participant who by week four in addition to having his 
dose of aripiprazole increased to 30 mg/day was also 
treated with diazepam, chlorpromazine, benztropine and 
clonazepam. Another participant was treated concurrently 
with aripiprazole (10 mg/day) sodium valproate (1,000 
mg/day), but was switched from aripiprazole to quetiapine 
after 1 month, and later to lithium and venlafaxine. Two 
other participants were treated concurrently with aripipra-
zole and diazepam. A further participant was treated con-
currently with aripiprazole and risperidone consta.
A 25 year old female who presented with psychotic symp-
toms discontinued treatment with aripiprazole (5 mg/day) 
due akathisia after receiving a dose of 5 mg/day concurrent 
with 20 mg/day of fluoxetine. She had been treated with 
fluoxetine monotherapy for a separate episode the per-
vious year. Aripiprazole was discontinued and the partic-
ipant recovered with fluoxetine monotherapy. A 21 year 
old male patient was switched to risperidone after 24 
weeks of aripiprazole treatment (10-15 mg/day) due to 
gastrointestinal effects. A 23 year old male switched to 
olanzapine after 24 weeks of aripiprazole treatment 
(15-30 mg/day) due to motor restlessness. Aripiprazole 
was withdrawn from a further two participants due to lack 
of efficacy and from one other due to non-adherence. No 
reason for discontinuation of aripiprazole was recorded 
for any of the other study participants.
Significant improvement in mean clinical outcomes, 
measured using the BPRS and CGI, were observed by 
week 6 and remained superior to baseline throughout the 
48-week study. Similar improvements were measured in 
social, occupational and global function, using the 
SOFAS and GAF scales, from week 4 and remaining su-
perior to baseline throughout the 48-week study (Table 2).
All 12 participants completed the Health of the Nation 
Outcomes Scales (HoNOS) at baseline. The median 
HoNOS total score was 13 (Interquatile range (IQR) 
12-14; Min 8; Max 38). The HoNOS was completed in re-
lation to 10 participants at 24-weeks with the median total 
score 4 (IQR 4-7; Min 2; Max 19) and on 3 participants at 
48-weeks with total scores 7, 8 and 14. Eleven participants 
completed the 16-item Life Skills Profile (LSP-16) at 
baseline. The median LSP-16 score was 14 (IQR 7-17; 
Min 2; Max 19). 10 participants at 24-weeks with the me-
dian total score 10 (IQR 3-12; Min 0; Max 25) and by 3 
participants at 48-weeks with total scores 1, 12 and 19. At 
4-weeks, 12 participants completed an 18 item Suicide 
Risk Assessment scale, with the lowest possible total 
score 18 and highest possible total score 54. The median 
total score was 25 (IQR 22-30; Min 20, Max 31).
At 4-weeks, the substance use indicator, which meas-
ures days of use for licit and illicit substances within the 
last 30 days, was completed by 11 participants. The partic-
ipant who did not complete the substance use indicator 
was a known polysubstance user. The lowest possible total 
score was 0 and highest possible total score was 300. The 
median total score was 31 (IQR 0-71; Min 0, Max 116). 
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An early psychosis flag, administered at week 4, was in-
cluded as clinician rated measure, where clinicians could 
choose the following options: 0= no answer, 1=possible 
an early psychosis, or 2=definitely early psychosis 
patient. Four participants were flagged for possible early 
psychosis and 5 participants were flagged for definite ear-
ly psychosis. At 24-weeks the BASIS-32 was conducted 
on 3 participants with scores of 3, 23 and 38 measured.
Physical health concerns included one participant with 
hepatitis C, one with diabetes and one who had been sig-
nificantly injured in a motor vehicle accident 6 weeks pri-
or to a first psychotic episode. Height and weight were 
measured on some occasions with three participants 
measured with a BMI in the normal range (18-25) at the 
commencement of the study, one participant who was 
overweight (BMI 26.8) and one who was underweight 
(BMI 17.5). One participant with a BMI at the low end of 
the normal range was remeasured 26 months later and had 
increased weight by 8 kg, but still had a normal BMI. BMI 
was not recorded on any occasion for the other 7 partic-
ipants, but of them one participant was described as lean 
and tall, one had weight loss, one was overweight and an-
other had been discontinued from olanzapine due to 
weight gain. One weighed 54.8 kg but height was not 
recorded.
Results of blood tests were available for 9 participants 
dating to various stages throughout the study. Abnormal 
liver function test results included 4 participants with ele-
vated alanine aminotransferase (ALT) and aspartate ami-
notransferase (AST), one of which also had elevated red 
cell folate and elevated cholesterol and another with ele-
vated bicarbonate and hepatitis C. One participant had 
lowered counts of white cells and neutrophils and a raised 
mean cell haemoglobin concentration (MCHC).
An ECG from one participant found a non-specific in-
traventricular block with QRS duration 174 ms (normal
＜140 ms) two days after commencing treatment with 
aripiprazole. An ECG was not conducted before com-
mencing treatment.
DISCUSSION
Of the12 study participants treated with Aripiprazole, 
only one maintained stable treatment with aripiprazole. 
The dose for that patient was stable at 15 mg/day. The 
highest dose used was 30 mg/day, given to 2 participants, 
one whose dose was subsequently lowered to 20 mg/day 
and was then switched to treatment with olanzapine, and 
another who was maintained on 30 mg/day of aripiprazole 
for 73 days before switching to olanzapine. Only one par-
ticipant was stabilised on aripiprazole at 48-weeks, how-
ever only three participants were stabilised on mono-
therapy at 48-weeks. The other two participants were sta-
bilised on risperidone consta and escitalopram, respectively.
Participants improved significantly during their period 
of treatment at the specialized early intervention service. 
Discontinuation of aripiprazole was based on either a de-
cision by the treating clinician, the patient, or in one case, 
non-compliance. The clinician’s decision to switch or dis-
continue a medication was made on an individual case- 
by-case basis and may be due to concerns about efficacy 
or tolerability, or due to changes in the patient’s symptoms.
In addition to treatment with Aripiprazole, other non- 
pharmacological interventions were offered to partic-
ipants as part of routine case management.
Treatment discontinuation is common in young people. 
In the CATIE study, a large (N=1,493) head-to-head com-
parison of antipsychotic drugs, there was a highly sig-
nificant association (p＜0.001) between younger age and 
time to discontinuation of treatment.16) In a study of pa-
tients aged 18 to 45 years with first-episode schizophrenia 
spectrum disorder (N=547), negative attitudes towards 
medication and lack of consistent family support sig-
nificantly predicted poor adherence to medication at a 
1-year follow up visit (p＜0.05). At a 2-year follow up vis-
it younger age, lack of a positive attitude towards medi-
cation and higher functioning additionally predicted poor 
adherence to medication (p＜0.005). In this study, adher-
ence rates to treatment were 51% at 1 year, and 44% at 2 
years.17) This suggests that the high rate of discontinuation 
of aripiprazole in the study described here may be at least 
in part characteristic of first episode psychosis. 
There were several limitations with the study. Firstly, 
the sample size was very small and the duration of treat-
ment with aripiprazole was short for most participants. All 
12 participants had a history of illicit substance use, which 
may have contributed to both psychotic illness and diffi-
culties with adherence and engagement. Family and social 
support varied considerably between participants. Conse-
quently, there was insufficient data to determine the opti-
mal dose for aripiprazole in first episode psychosis, how-
ever doses up to 30 mg/day were used safely in this study. 
Similarly, it was not possible to definitively conclude a 
causal link between aripiprazole treatment and clinical 
improvement in the 12 patients, for which large placebo 
controlled trails in a first episode population are nece-
ssary. Changes in medication for most patients during the 
course of the study were an additional confound. This 
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study was not designed to investigate the efficacy and tol-
erability of aripiprazole in a population group of young 
people as it was not randomised and did not have a placebo 
control. As such it is not possible to definitively determine 
what role aripiprazole had in the clinical improvement 
demonstrated by most participants during the study 
period. 
Young people with first episode psychosis require dif-
ferent management compared to patients with chronic 
schizophrenia. First episode patients presenting to a spe-
cialist early intervention service often have non-specific 
symptomatology, and require individualised treatment re-
gimes, which can include a range of medications as well as 
non-pharmacological interventions. Issues with illness 
acceptance, adherence and engagement predominate in 
younger first episode illness, and comorbidities such as 
substance abuse are more common. However, drug effi-
cacy data is obtained from clinical trials predominantly 
conducted on older, more chronic patients. Further re-
search is required to optimise interventions to treat first 
episode psychosis in young people.
This study was funded by a research grant from Bristol- 
Myers Squibb.
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